Delivery of Islatravir via High Drug‐Load, Long‐acting Microarray Patches for the Prevention or Treatment of Human Immunodeficiency Virus

• DOI: 10.1002/adhm.202403615
• Publication Date: 2025-01-22T10:14:48Z
• Authors: Qonita Kurnia Anjani; Ashley R. Johnson; Akmal H. Sabri; Ryan Lutz; Steven Tignor; Jeanine Ballard; Nathan Rudd; Li Zhao; Lalitkumar K. Vora; Stephanie E. Barrett; Angela Wagner; Ryan F. Donnelly
• Keywords: treatment; prevention; /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being; 500; HIV; high drug‐load; /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being; name=SDG 3 - Good Health and Well-being; microarray patches; islatravir; long‐acting; name=SDG 3 - Good Health and Well-being; Research Article

Abstract This research focuses on developing and characterizing islatravir‐loaded dissolving microarray patches (MAPs) to provide an effective, minimally invasive treatment option for human immunodeficiency virus (HIV‐1) prevention treatment. The involves manufacturing these MAPs using a double‐casting approach, conducting in vitro vivo evaluations. Results show that the have excellent needle fidelity, structural integrity, mechanical strength. studies demonstrate can penetrate skin up 580 µm dissolve within 2 hours. Permeation reveal delivery efficiency of islatravir across is around 40%. In rodent models, sustain 3 months. Scaling increasing drug loading produced detectable levels minipig. Projections from animal data suggest achieve effective month after single application humans. These findings indicate as approach sustained release islatravir.